AFT Pharmaceuticals

Expansion or Overextension? The Risks Behind AFT’s Global Push.

Robbo

Not Invested

Community Contributor

Published

29 Sep 25

Robbo's Fair Value

NZ$2.80

0.7% undervalued

29 Sep

NZ$2.78

-12.0%

6.1%

-12.0%

6.1%

You can edit this narrative until Sep 30 4:16 AM. Then, changes will post as Updates.

Author's Valuation

NZ$2.8

0.7% undervalued

Robbo's Fair Value

Narrative

Updates0

Robbo'sFair Value

NZ$2.8

0.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

11.02%

Pharma revenue growth rate

0.70%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.90%

Calculation

NZ$16.82m

Earnings '30

24.37x

PE Ratio '30

NZ$409.84m

Market Cap '30

NZ$409.84m

Market Cap '30

104.87m

No. shares '30

NZ$3.91

Share Price '30

NZ$3.91 Share Price '30

Discounted to 2025 @ 6.90% p.a.

NZ$2.80

Fair Value '25